With regard to molecular testing, it is recommended to perform BRAF and RAS gene mutation analyses on somatic cells from patients with papillary thyroid carcinoma (PTC) and medullary thyroid carcinoma (MTC), respectively, while RET genetic testing should be conducted on both somatic and germline DNA. This evidence concerns the gene BRAF and medullary thyroid gland carcinoma.